Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing

Expert Opinion on Drug Metabolism & Toxicology
M B Abelson, Paul J Gomes

Abstract

Olopatadine 0.2% is the first topical ophthalmic antihistamine/mast cell stabilizer indicated for once-daily dosing. This review provides a comprehensive description of the pharmacology of the olopatadine molecule, as well as of the clinical efficacy, tolerability, and safety of olopatadine 0.2% ophthalmic solution. References cited in this review were obtained from the PubMed biomedical literature database. Also included were several posters presented at nationally renowned ophthalmology-related conferences. Olopatadine 0.2% was found to be a safe and effective medication for the reduction of itching with a duration of action of up to 24 h. The added convenience of a once-a-day dosing regimen is a major advancement in this drug class.

References

Jan 1, 1990·Archives of Ophthalmology·M B AbelsonL M Smith
Jan 1, 1996·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·J M YanniD A Gamache
Jan 1, 1996·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·N A SharifJ M Yanni
Jan 20, 1998·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·J M YanniN A Sharif
May 21, 1998·European Journal of Pharmacology·H NonakaM Ichimura
Oct 6, 1998·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·M B Abelson
Jun 1, 2000·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·E B CookF M Graziano
Nov 1, 2000·Acta Ophthalmologica Scandinavica. Supplement·H BrockmanJ Yanni
Nov 1, 2000·Acta Ophthalmologica Scandinavica. Supplement·M Brodsky
Nov 1, 2000·Acta Ophthalmologica Scandinavica. Supplement·M N ArtalM Discepola
Jul 11, 2001·Optometry and Vision Science : Official Publication of the American Academy of Optometry·R du ToitD Fonn
Dec 4, 2001·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·E B CookF M Graziano
Jan 6, 2004·Ocular Immunology and Inflammation·Howard L BrockmanJohn M Yanni
Feb 6, 2004·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Ellen B CookFrank M Graziano
Aug 25, 2004·Current Medical Research and Opinion·Bobby Q LanierGreg L Ledgerwood
Nov 11, 2005·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·William BergerStanley Galant
May 17, 2006·Primary Care Respiratory Journal : Journal of the General Practice Airways Group·Julian F GuestMark J Greener
Nov 1, 2006·The Ocular Surface·Mark B AbelsonMatthew Chapin
Sep 7, 2007·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Steven J LichtensteinStella M Robertson
Sep 22, 2007·Allergy and Asthma Proceedings·Mark B AbelsonStella M Robertson

❮ Previous
Next ❯

Citations

Mar 26, 2011·Current Allergy and Asthma Reports·Mark B AbelsonPaul J Gomes
May 24, 2014·Pediatric Clinics of North America·Virginia Miraldi Utz, Aaron R Kaufman
Sep 12, 2013·Ophthalmology·Thomas R WaltersUNKNOWN Bromfenac Ophthalmic Solution 0.07% Once Daily Study Group
Nov 3, 2009·Contact Lens & Anterior Eye : the Journal of the British Contact Lens Association·DeGaulle I Chigbu
Jul 2, 2015·European Journal of Pharmacology·Tao ZhangJohn Jarlath Walsh
Aug 27, 2013·Current Opinion in Allergy and Clinical Immunology·Punchama Pacharn, Pakit Vichyanond
Mar 24, 2010·Expert Opinion on Pharmacotherapy·Andrea Leonardi, Luigi Quintieri
Apr 24, 2018·Journal of Pharmacokinetics and Pharmacodynamics·Matthew L FidlerRamesh Sarangapani

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.